Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase

被引：0
|
作者：
Lee, Ji Yun [1 ]
Lim, Sung Hee [1 ]
Kim, Hae Su [1 ]
Yoo, Kwai Han [1 ]
Song, Haa-Na [1 ]
Cho, Jinhyun [1 ]
Park, Silvia [1 ]
Kim, Seok Jin [1 ]
Kim, Won Seog [1 ]
Kim, Kihyun [1 ]
Jang, Jun Ho [1 ]
Jung, Chul Won [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Albano, F.
    Abruzzese, E.
    Levato, L.
    Cavazzini, F.
    Lurlo, A.
    Stagno, F.
    Ferrero, D.
    Porretto, F.
    Martino, B.
    Rupoli, S.
    Intermesoli, T.
    Fava, C.
    Pierri, I.
    Palandri, F.
    Venturi, C.
    Soverini, S.
    Luatti, S.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Cavo, M.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2013, 98 : 59 - 59
  • [22] Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
    Okamoto, Yuji
    Hirano, Mitsuhito
    Morino, Kai
    Kajita, Masashi K.
    Nakaoka, Shinji
    Tsuda, Mayuko
    Sugimoto, Kei-ji
    Tamaki, Shigehisa
    Hisatake, Junichi
    Yokoyama, Hisayuki
    Igarashi, Tadahiko
    Shinagawa, Atsushi
    Sugawara, Takeaki
    Hara, Satoru
    Fujikawa, Kazuhisa
    Shimizu, Seiichi
    Yujiri, Toshiaki
    Wakita, Hisashi
    Nishiwaki, Kaichi
    Tojo, Arinobu
    Aihara, Kazuyuki
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2022, 8 (01)
  • [23] Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
    Brectia, Massimo
    Molica, Matteo
    Colafigli, Gioia
    Massaro, Fulvio
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2016, 48 : 20 - 25
  • [24] Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
    Yuji Okamoto
    Mitsuhito Hirano
    Kai Morino
    Masashi K. Kajita
    Shinji Nakaoka
    Mayuko Tsuda
    Kei-ji Sugimoto
    Shigehisa Tamaki
    Junichi Hisatake
    Hisayuki Yokoyama
    Tadahiko Igarashi
    Atsushi Shinagawa
    Takeaki Sugawara
    Satoru Hara
    Kazuhisa Fujikawa
    Seiichi Shimizu
    Toshiaki Yujiri
    Hisashi Wakita
    Kaichi Nishiwaki
    Arinobu Tojo
    Kazuyuki Aihara
    npj Systems Biology and Applications, 8
  • [25] Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
    Linga, Vijay Gandhi
    Ganta, Ranga Raman
    Kalpathi, Krishnamani Iyer
    Gundeti, Sadashivudu
    Rajappa, Senthil J.
    Digumarti, Raghunadharao
    Paul, Tara Roshni
    Tandon, Ashwani
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (04) : 203 - 205
  • [26] Response to imatinib mesylate in late chronic phase chronic myeloid leukemia
    Mukhopadhyay, S.
    Chitalkar, P. G.
    Gupta, P. R.
    Roy, U.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 41
  • [27] PREDICTORS OF STABLE DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH DASATINIB OR NILOTINIB AFTER IMATINIB FAILURE
    Bonifacio, M.
    Binotto, G.
    Tiribelli, M.
    Scaffidi, L.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    Frison, L.
    De Marchi, F.
    Medeot, M.
    Bucelli, C.
    Calistri, E.
    Stulle, M.
    Gherlinzoni, F.
    Cortelezzi, A.
    Fanin, R.
    Semenzato, G.
    Krampera, M.
    Pizzolo, G.
    Ambrosetti, A.
    HAEMATOLOGICA, 2016, 101 : S74 - S74
  • [28] Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase
    Akard, Luke P.
    Bixby, Dale
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1002 - 1014
  • [29] Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
    Li, Zongru
    Zhang, Xiaoshuai
    Zhao, Yijing
    Lu, Linping
    Guo, Yong
    Gale, Robert Peter
    Qin, Yazhen
    Jiang, Qian
    CANCER, 2025, 131 (01)
  • [30] Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Garcia-Manero, G
    Giles, F
    Shan, J
    Verstovsek, S
    Rios, MB
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 81A - 81A
12345